Freezing shock monocytes deliver antisense oligonucleotides via liposomes for the treatment of idiopathic pulmonary fibrosis
Hailong Li , Xi Wu , Jinhe Li , Liqing Han , Hongting Liu , Qiuyan Jiang , Bowen Liu , Qin Xia , Zherui Li , Xiaohe Li , Songtao Gu , Aiguo Xu , Honggang Zhou , Xiaoting Gu , Zuojun Xu , Xiaoyu Ai , Cheng Yang
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101128
Connective tissue growth factor (CTGF) is a key driver in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study presents a groundbreaking supramolecular cryo-shock bone marrow mononuclear cell system for targeted drug delivery in IPF. We incorporated antisense oligonucleotides (ASO) to inhibit CTGF and simultaneously encapsulated nintedanib using the ZMO-E5-NPs carrier for synergistic delivery. The cryo-shock treatment enhances cellular structural integrity and preserves receptor functionality, thereby extending cell viability. By modifying the E5 peptide and conjugating it with DSPE-PEG-MAL, we developed a composite carrier, ZMO-E5-NPs, which demonstrates efficient lung-targeting capability. This system enables rapid nanoparticle capture by fibroblasts through matrix metalloproteinase 2 (MMP2) recognition, ensuring precise delivery of both ASO and nintedanib. In a bleomycin-induced pulmonary fibrosis mouse model, ZMO-E5-NPs-ASO (nintedanib-containing group) significantly attenuated fibrosis progression, improved lung function, and exhibited excellent biocompatibility and safety, highlighting its potential as a novel therapeutic strategy for respiratory diseases.
Connective tissue growth factor / Idiopathic pulmonary fibrosis / Antisense oligonucleotides / Nintedanib / Matrix metalloproteinase 2 / Lung function
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
Hayek H, Rehbini O, Kosmider B, Brandt T, Chatila W, Marchetti N, |
| [10] |
|
| [11] |
|
| [12] |
Leask A. Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis. J Cell Commun Signal 2019; 13: 441-2. |
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
Kassassir H, Papiewska-Pajak I, Kryczka J, Boncela J, Kowalska MA. Platelet-derived microparticles stimulate the invasiveness of colorectal cancer cells via the p38MAPK-MMP-2/MMP-9 axis. Cell Commun Signal 2023; 21: 51. |
| [25] |
|
| [26] |
|
| [27] |
Pan L, Cheng Y, Yang W, Wu X, Zhu H, Hu M, et al. Nintedanib ameliorates bleomycin-induced pulmonary fibrosis, inflammation, apoptosis, and oxidative stress by modulating the PI3K/Akt/mTOR pathway in mice. Inflammation 2023;46:1531-42. |
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
Song S, Fu Z, Guan R, Zhao J, Yang P, Li Y, |
/
| 〈 |
|
〉 |